Pfizer has announced impressive second-quarter earnings, surpassing Wall Street expectations with a revenue growth of 10% year-over-year, amounting to $14.65 billion. In light of these gains, the pharmaceutical giant has raised its profit forecast for 2025, attributing this positive shift to successful cost-cutting measures that offset ongoing pricing pressures and weaker sales growth. The stock experienced a notable increase following the earnings report, reflecting investor confidence as the company adapts to market challenges and enhances its long-term profitability outlook.